Expanding Footprints of Biosimilar Tenecteplase.
作者信息
Yada Praveen K
机构信息
Department of Neurology, Krishna Institute of Medical Sciences, Secunderabad, Telangana, India.
出版信息
Ann Indian Acad Neurol. 2023 May-Jun;26(3):219-220. doi: 10.4103/aian.aian_256_23. Epub 2023 Apr 24.
Abstract
摘要
相似文献
1
Expanding Footprints of Biosimilar Tenecteplase.生物类似药替奈普酶的应用范围不断扩大。
Ann Indian Acad Neurol. 2023 May-Jun;26(3):219-220. doi: 10.4103/aian.aian_256_23. Epub 2023 Apr 24.
2
Comparison of clot lysis activity and biochemical properties of originator tenecteplase (Metalyse(®)) with those of an alleged biosimilar.比较原研替奈普酶（Metalyse(®)）与疑似生物类似药的纤溶活性和生化特性。
Front Pharmacol. 2014 Feb 5;5:7. doi: 10.3389/fphar.2014.00007. eCollection 2014.
3
Biosimilarity. Do not confuse biosimilar and biocopy. Example of tenecteplase.生物相似性。不要将生物相似药与生物仿制药混淆。以替奈普酶为例。
Ann Pharm Fr. 2023 Nov;81(6):942-949. doi: 10.1016/j.pharma.2023.07.001. Epub 2023 Jul 6.
4
Biosimilar Tenecteplase Versus Alteplase in Acute Ischemic Stroke: A Real World Study.生物类似药替奈普酶与阿替普酶治疗急性缺血性卒中的真实世界研究
Ann Indian Acad Neurol. 2023 Jan-Feb;26(1):54-58. doi: 10.4103/aian.aian_754_22. Epub 2023 Jan 4.
5
Using Tenecteplase for Acute Ischemic Stroke: What Is the Hold Up?使用替奈普酶治疗急性缺血性脑卒中：为何还未普及？
West J Emerg Med. 2020 Feb 24;21(2):199-202. doi: 10.5811/westjem.2020.1.45279.
6
Intravenous tenecteplase in acute ischemic stroke: an updated review.急性缺血性卒中的静脉注射替奈普酶：最新综述
J Neurol. 2014 Jun;261(6):1069-72. doi: 10.1007/s00415-013-7102-0. Epub 2013 Sep 15.
7
Issues in the assessment of the safety and efficacy of tenecteplase (TNK-tPA).替奈普酶（TNK-tPA）安全性和有效性评估中的问题。
Clin Cardiol. 2001 Sep;24(9):577-84. doi: 10.1002/clc.4960240903.
8
Tenecteplase or Alteplase: What Is the Thrombolytic Agent of the Future?替奈普酶还是阿替普酶：未来的溶栓药物是什么？
Curr Treat Options Neurol. 2022;24(10):503-513. doi: 10.1007/s11940-022-00733-4. Epub 2022 Jul 30.
9
Tenecteplase in Acute Stroke: What About the Children?替奈普酶治疗急性脑卒中：儿童患者如何？
Stroke. 2023 Jul;54(7):1950-1953. doi: 10.1161/STROKEAHA.123.042951. Epub 2023 May 25.
10
Safety and efficacy of tenecteplase in acute myocardial infarction.替奈普酶在急性心肌梗死中的安全性和有效性。
Expert Opin Pharmacother. 2003 May;4(5):791-8. doi: 10.1517/14656566.4.5.791.
本文引用的文献
1
Biosimilar Tenecteplase Versus Alteplase in Acute Ischemic Stroke: A Real World Study.生物类似药替奈普酶与阿替普酶治疗急性缺血性卒中的真实世界研究
Ann Indian Acad Neurol. 2023 Jan-Feb;26(1):54-58. doi: 10.4103/aian.aian_754_22. Epub 2023 Jan 4.
2
Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.加拿大急性缺血性脑卒中静脉内替奈普酶与阿替普酶比较（AcT）：一项实用的、多中心、开放标签、与登记系统相关联、随机化、对照、非劣效性试验。
Lancet. 2022 Jul 16;400(10347):161-169. doi: 10.1016/S0140-6736(22)01054-6. Epub 2022 Jun 29.
3
Tenecteplase vs. alteplase for acute ischemic stroke: a systematic review.替奈普酶与阿替普酶治疗急性缺血性卒中的系统评价
Int J Emerg Med. 2022 Jan 4;15(1):1. doi: 10.1186/s12245-021-00399-w.
4
European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke.欧洲卒中组织（ESO）急性缺血性卒中静脉溶栓指南。
Eur Stroke J. 2021 Mar;6(1):I-LXII. doi: 10.1177/2396987321989865. Epub 2021 Feb 19.
5
Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.急性缺血性脑卒中患者早期管理指南：2018 年急性缺血性脑卒中早期管理指南的更新：美国心脏协会/美国卒中协会发布的医疗保健专业人员指南。
Stroke. 2019 Dec;50(12):e344-e418. doi: 10.1161/STR.0000000000000211. Epub 2019 Oct 30.
6
Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials.急性缺血性脑卒中静脉注射替奈普酶推注的疗效和安全性：两项开放标签、多中心试验的结果。
Am J Cardiovasc Drugs. 2018 Oct;18(5):387-395. doi: 10.1007/s40256-018-0284-1.
7
Tenecteplase versus alteplase before endovascular thrombectomy (EXTEND-IA TNK): A multicenter, randomized, controlled study.替奈普酶与血管内血栓切除术前的阿替普酶（EXTEND-IA TNK）：一项多中心、随机、对照研究。
Int J Stroke. 2018 Apr;13(3):328-334. doi: 10.1177/1747493017733935. Epub 2017 Sep 27.
8
Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial.替奈普酶与阿替普酶治疗急性缺血性脑卒中的比较（NOR-TEST）：一项 3 期、随机、开放标签、盲终点试验。
Lancet Neurol. 2017 Oct;16(10):781-788. doi: 10.1016/S1474-4422(17)30253-3. Epub 2017 Aug 2.
9
Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.阿替普酶与替奈普酶治疗缺血性脑卒中溶栓（ATTEST）：一项 2 期、随机、开放标签、盲终点研究。
Lancet Neurol. 2015 Apr;14(4):368-76. doi: 10.1016/S1474-4422(15)70017-7. Epub 2015 Feb 26.
10
A randomized trial of tenecteplase versus alteplase for acute ischemic stroke.替奈普酶与阿替普酶治疗急性缺血性脑卒中的随机试验。
N Engl J Med. 2012 Mar 22;366(12):1099-107. doi: 10.1056/NEJMoa1109842.
Zotero 插件